| Title |
Systemic delivery of chTNT-3/CpG immunoconjugates for immunotherapy in murine solid tumor models
|
|---|---|
| Published in |
Cancer Immunology, Immunotherapy, March 2016
|
| DOI | 10.1007/s00262-016-1813-x |
| Pubmed ID | |
| Authors |
Julie K. Jang, Leslie A. Khawli, David C. Canter, Peisheng Hu, Tian H. Zhu, Brian W. Wu, Trevor E. Angell, Zhongjun Li, Alan L. Epstein |
| Abstract |
CpG oligodeoxynucleotides (CpG) potently activate the immune system by mimicking microbial DNA. Conjugation of CpG to chTNT-3, an antibody targeting the necrotic centers of tumors, enabled CpG to accumulate in tumors after systemic delivery, where it can activate the immune system in the presence of tumor antigens. CpG chemically conjugated to chTNT-3 (chTNT-3/CpG) were compared to free CpG in their ability to stimulate the immune system in vitro and reduce tumor burden in vivo. In subcutaneous Colon 26 adenocarcinoma and B16-F10 melanoma models in BALB/c and C57BL/6 mice, respectively, chTNT-3/CpG, free CpG, or several different control constructs were administered systemically. Intraperitoneal injections of chTNT-3/CpG delayed tumor growth and improved survival and were comparable to intratumorally administered CpG. Compared to saline-treated mice, chTNT-3/CpG-treated mice had smaller average tumor volumes by as much as 72 % in Colon 26-bearing mice and 79 % in B16-bearing mice. Systemically delivered free CpG and CpG conjugated to an isotype control antibody did not reduce tumor burden or improve survival. In this study, chTNT-3/CpG retained immunostimulatory activity of the CpG moiety and enabled delivery to tumors. Because systemically administered CpG rapidly clear the body and do not accumulate into tumors, chTNT-3/CpG provide a solution to the limitations observed in preclinical and clinical trials. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 50% |
| Science communicators (journalists, bloggers, editors) | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 29 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 29 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 11 | 38% |
| Student > Bachelor | 4 | 14% |
| Student > Ph. D. Student | 2 | 7% |
| Student > Master | 2 | 7% |
| Professor | 1 | 3% |
| Other | 2 | 7% |
| Unknown | 7 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 6 | 21% |
| Biochemistry, Genetics and Molecular Biology | 5 | 17% |
| Agricultural and Biological Sciences | 5 | 17% |
| Immunology and Microbiology | 2 | 7% |
| Chemistry | 2 | 7% |
| Other | 1 | 3% |
| Unknown | 8 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 March 2024.
All research outputs
#4,980,131
of 24,727,020 outputs
Outputs from Cancer Immunology, Immunotherapy
#497
of 2,933 outputs
Outputs of similar age
#72,338
of 305,707 outputs
Outputs of similar age from Cancer Immunology, Immunotherapy
#12
of 39 outputs
Altmetric has tracked 24,727,020 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,933 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.4. This one has done well, scoring higher than 82% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 305,707 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 76% of its contemporaries.
We're also able to compare this research output to 39 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.